Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Reduction of Intraocular Pressure With Anecortave Acetate in Eyes With Ocular Steroid Injection–Related Glaucoma

Reduction of Intraocular Pressure With Anecortave Acetate in Eyes With Ocular Steroid... CLINICAL SCIENCES Reduction of Intraocular Pressure With Anecortave Acetate in Eyes With Ocular Steroid Injection–Related Glaucoma Alan L. Robin, MD; Eric P. Suan, MD; Raymond N. Sjaarda, MD; David G. Callanan, MD; Joseph DeFaller, PhD†; for the Alcon Anecortave Acetate for IOP Research Team Objective: To evaluate the intraocular pressure (IOP)– Results: The mean baseline IOP was 39.9 mm Hg. After lowering potential of anecortave acetate (AA) in eyes with 1 week, the mean IOP decreased 12 mm Hg (29%; P = .005) steroid-related ocular hypertension inadequately con- and by 1 month, the mean IOP had decreased 14.1 mm Hg trolled with the maximal tolerated or appropriate medi- (34.5%; P = .003) from baseline. Four eyes required surgi- cal therapy. cal intervention despite a decrease in IOP because of mark- edly elevated initial IOP and the degree of preexisting glau- Design: Uncontrolled case series. comatous optic neuropathy. We observed no adverse events. Methods: A total of 8 eyes of 7 subjects with medically Conclusions: An anterior juxtascleral depot of AA low- uncontrolled IOP following intravitreal or sub-Tenon in- ers IOP substantially in some eyes with medically un- jections of triamcinolone acetonide were included. All controlled steroid-related ocular hypertension. Further http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Ophthalmology American Medical Association

Reduction of Intraocular Pressure With Anecortave Acetate in Eyes With Ocular Steroid Injection–Related Glaucoma

Loading next page...
 
/lp/american-medical-association/reduction-of-intraocular-pressure-with-anecortave-acetate-in-eyes-with-E2gMT6kwuF

References (19)

Publisher
American Medical Association
Copyright
Copyright 2009 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
2168-6165
eISSN
2168-6173
DOI
10.1001/archophthalmol.2008.595
pmid
19204235
Publisher site
See Article on Publisher Site

Abstract

CLINICAL SCIENCES Reduction of Intraocular Pressure With Anecortave Acetate in Eyes With Ocular Steroid Injection–Related Glaucoma Alan L. Robin, MD; Eric P. Suan, MD; Raymond N. Sjaarda, MD; David G. Callanan, MD; Joseph DeFaller, PhD†; for the Alcon Anecortave Acetate for IOP Research Team Objective: To evaluate the intraocular pressure (IOP)– Results: The mean baseline IOP was 39.9 mm Hg. After lowering potential of anecortave acetate (AA) in eyes with 1 week, the mean IOP decreased 12 mm Hg (29%; P = .005) steroid-related ocular hypertension inadequately con- and by 1 month, the mean IOP had decreased 14.1 mm Hg trolled with the maximal tolerated or appropriate medi- (34.5%; P = .003) from baseline. Four eyes required surgi- cal therapy. cal intervention despite a decrease in IOP because of mark- edly elevated initial IOP and the degree of preexisting glau- Design: Uncontrolled case series. comatous optic neuropathy. We observed no adverse events. Methods: A total of 8 eyes of 7 subjects with medically Conclusions: An anterior juxtascleral depot of AA low- uncontrolled IOP following intravitreal or sub-Tenon in- ers IOP substantially in some eyes with medically un- jections of triamcinolone acetonide were included. All controlled steroid-related ocular hypertension. Further

Journal

JAMA OphthalmologyAmerican Medical Association

Published: Feb 1, 2009

There are no references for this article.